This newsletter is part of a series — here are the links to Part 1, Part 2, Part 3, (this one is Part 4), and Part 5. Dear All, We had fun in Feb 2020 discussing whether an antibacterial compound discovered using machine learning was a drug or just a chemical. Building on that conversation, the lab that wrote the
Dear All, Happy New Year! I hope you were able to relax with friends and family during the year-end festivities! I have a small backlog of notes that will follow over the next few days but for tonight we have a brief note about a funding opportunity with a short timeline. JPIAMR have today opened an
Dear All, Exciting additional news merits two newsletters in one day! I’ll keep it brief and quote directly from the website: “Innovate UK, LifeArc, and Medicines Discovery Catapult (MDC) have joined forces to create PACE (Pathways to Antimicrobial Clinical Efficacy), a £30 million initiative supporting early-stage innovation against antimicrobial resistance (AMR) to save lives. PACE has today (19 October 2023) announced
Note: For those of you with an interest in developing bacterial vaccines, the results of Pfizer’s failed STRIVE S. aureus vaccine have now appeared in print along with an excellent editorial commentary. Deep sigh on this one — please see the updated prior newsletter for the links and the full story. This newsletter is part
Dear All, Some great news today! We have visible evidence of global government action in support of the addressing our antibiotic gaps. First, CARB-X has announced that Canada has now joined its coalition of funders with a pledge of $6.3m! Woot, woot! Go Team Canada! Second, the UK and Germany have renewed their funding support with commitments of GBP
Dear All, Today we have a collection of things all related to the global efforts to fight AMR. Two papers, a webinar, and a movie trailer! First, the Antibiotic Access and Use (ABACUS) project has released a very interesting paper entitled “Is this pill an antibiotic or a painkiller? Improving the identification of oral antibiotics
Dear All, I wrote in 2018 about National Cancer Institute’s Natural Products Branch (NPB) and its program for Natural Product Discovery (NPNPD) as a resource for antimicrobial discovery. In brief, it’s a global collection of natural products that is available as a library of semi-pure natural product samples that comes pre-platted in 384-well plates. The deep idea behind
Dear All, During their recent turn to hold the EU presidency (1 Jan to 30 Jun 2023), the Swedes have steadily pushed AMR as one of their top priorities. As part of this, Sweden used their most recent presidency to release a motion to adopt a Council Recommendation on fighting AMR. Here are the parallel links that
Dear All, As a follow up to the glorious cacophony of the events occurring right at the end of April, Kevin Outterson and I made time to discuss all that has happened. The PASTEUR Act reintroduced, the AMR House Subcommittee hearing, the European Commission proposals, the CARB-X Annual Report, FDA approval of the first microbiome-based therapeutic …
Dear All, Two items for your attention today: an immediate action for you to take to support PASTEUR plus a launch event for a major Wellcome Trust project for your calendar. First, as you may recall, the Oversights & Investigations Subcommittee of the US House Energy & Commerce Committee recently held a hearing about the impact of AMR.